Emicizumab (1.5-10 mg/kg, IV, 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia A bleeding model, with an FVIII equivalence of 9 U/dL[1].
Emicizumab (3 mg/kg, IV) provides additive hemostatic activity when given in combination with low-dose FVIII (10 U/dL)[1].
| Animal Model: | FVIII-deficient mice[1] |
| Dosage: | 1.5-10 mg/kg |
| Administration: | IV, 24 hours before tail-clip bleeding was performed |
| Result: | Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice. |
